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Anticoagulation in Addition to Aspirin in Unstable Angina
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators
OBJECTIVES We sought to evaluate whether oral anticoagulant (AC) therapy given for five months was
superior to standard (control) therapy in patients with unstable angina receiving aspirin.
BACKGROUND The long-term risk of myocardial infarction (MI) or death remains high in patients with
unstable angina, despite the use of aspirin. Therefore, additional treatments are necessary.
METHODS Of the 10,141 patients entering the main trial, 3,712 were randomized 12 to 48 h later to
receive oral AC therapy (n 5 1,848) or standard therapy (n 5 1,864).
RESULTS One-hundred forty patients (7.6%) suffered from cardiovascular death, MI or stroke while
receiving oral AC, compared with 155 patients (8.3%) on standard therapy (relative risk [RR]
0.90, 95% confidence interval [CI] 0.72 to 1.14; p 5 0.40). The rates of the primary outcomes
plus refractory angina were 16.7% (n 5 308) versus 17.5% (n 5 327) (RR 0.95, 95% CI 0.81
to 1.11; p 5 0.53). Countries were divided into good or poor compliers (based on the use of
oral AC above or below 70% at 35 days), without knowledge of results by country. In
good-complier countries, oral AC was discontinued in only 10.4% of patients at seven days
and in 23.6% by five months, compared with 27.6% and 44.9%, respectively, in poor complier
countries. There were significant reductions in the risks of both the primary (6.1% vs. 8.9%;
RR 0.68, 95% CI 0.48 to 0.95; p 5 0.02) and secondary outcomes (11.9% vs. 16.5%; RR 0.70,
95% CI 0.55 to 0.90; p 5 0.005) with oral AC in the good-complier countries. There was
little difference in the poor-complier countries (9.0% vs. 7.8% for the primary and 21.3% vs.
18.5% for the secondary outcomes, tests for interactions comparing the RRs for the primary
and secondary outcomes were p , 0.02 and p 5 0.002, respectively, between the two sets of
countries). In the overall study, there was an excess of major bleeding (2.7% vs. 1.3%; p 5
0.004), which was larger in the good-complier countries (RR 2.71) compared with the
poor-complier countries (RR 1.58). There were also reductions in cardiac catheterization (RR
0.80; p 5 0.004) and coronary revascularization procedures (RR 0.82; p 5 0.06) in the
good-complier countries, but not in the poor-complier countries (RR 0.98 and 1.06,
respectively, p for interaction of 0.06 and 0.04, respectively).
CONCLUSIONS Overall, oral AC led to a small, nonsignificant reduction in the risk of the primary and
secondary outcomes. Stratifying the countries or centers by their rates of compliance to oral
AC suggested that good compliance to oral AC could potentially lead to clinically important
reductions in major ischemic cardiovascular events. (J Am Coll Cardiol 2001;37:475– 84)
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Nonocclusive coronary thrombosis has been implicated
as a common cause of unstable angina (UA) (1). Anti-
thrombotic agents, such as heparin (2) or hirudin (3), and
antiplatelet agents, such as aspirin (4) or glycoprotein
IIb/IIIa receptor antagonists (5), are effective in decreas-
ing the risk of myocardial infarction (MI) or refractory
ischemia. Only long-term aspirin has been shown to
reduce the risk of cardiac deaths and MI in patients with
UA (6). Despite the use of aspirin, ;10% to 15% of
patients still experience death or MI by one year, and
;20% of patients are readmitted to the hospital with UA.
Recent angioscopic studies indicate that coronary
thrombi persist even at one month after the acute UA
episode in patients taking aspirin (7), and markers of
thrombin generation remain elevated in apparently
asymptomatic patients. These considerations suggest that
additional long-term antithrombotic strategies may be
potentially beneficial.
Oral anticoagulants (ACs) have been demonstrated to
reduce the risk of death, MI or stroke after acute MI (8).
However, these results are derived from trials in which
aspirin was not used, the intensity of anticoagulation was
high (International Normalized Ratio [INR] .2.8) and a
substantial degree of major bleeding occurred. We recently
conducted two pilot trials using varying intensities of
warfarin compared with standard (control) therapy in pa-
tients with UA receiving aspirin (9). These studies indicated
that low intensity (INR ,1.5) oral AC therapy was inef-
fective, whereas a moderate intensity (INR 2.0 to 2.5) was
promising. These results are supported by the results of a
previous small trial in which aspirin was concomitantly used
(10) and in several post-MI trials where aspirin was not used
(8). Therefore, in the Organization to Assess Strategies for
Ischemic Syndromes (OASIS-2) substudy, we evaluated the
effects of oral AC therapy (target INR 2.5) in addition to
aspirin, compared with aspirin alone, when given up to five
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months, on the composite outcome of cardiovascular death,
MI or stroke (primary outcome) and cardiovascular death,
MI, stroke and readmission to the hospital for UA (second-
ary outcome).
METHODS
Patients. Patients eligible for the main OASIS-2 trial,
which compared a three-day regimen of hirudin vs. heparin
(3), were those who could be randomized within 12 h of an
episode of chest pain suspected to be due to UA or MI
without ST segment elevation on their admission electro-
cardiogram. The diagnosis of UA was based on symptoms
of angina that were new in onset, worsening or occurring
with minimal activity. Detailed inclusion and exclusion
criteria for the main trial have been previously published.
Additional exclusions for the warfarin part of the study were
a clear indication for warfarin, bleeding during heparin or
hirudin, coronary artery bypass graft surgery planned within
a week, normal coronary anatomy, contraindications to oral
AC therapy and physician or patient reluctance.
Randomization and treatment regimens. The OASIS-2
trial utilized a partial 2 3 2 factorial design. Details of the
patients’ initial randomization to heparin or hirudin and
their treatment regimen have been published previously (3).
The AC therapy component (warfarin in all countries,
except for Hungary, where dicumarol was used) was a
randomized, open trial with blinded adjudication of out-
comes. Patients were randomized between 12 and 30 h after
the initial randomization to heparin or hirudin, but this
could be extended up to seven days in some circumstances.
Patients were randomized by a toll-free telephone call to a
24-h automated randomization service. After key data were
recorded, the patients were allocated to receive warfarin
(loading dose of 10 mg followed by 3 mg/day for two days)
or to a control group for five months. Further dosing
adjustments were based on the INR values and were aimed
to achieve an INR between 2.0 and 2.5. Patients were
followed at one, three and five months. All patients were
followed for another month to assess whether there was any
“rebound” in clinical events. All patients gave written,
informed consent, and the protocol was approved by the
Institutional Review Board of each hospital.
Outcomes. The primary follow-up period was five months.
The primary outcome was a comparison of the rates of
cardiovascular death, MI or strokes, and the secondary
analysis included these outcomes plus readmission to the
hospital for UA. Definitions for all outcomes have been
previously published (3).
Follow-up and blinded central adjudication of events.
The one-month data are available for 3,708 patients
(99.9%); three-month data for 3,703 patients (99.8%); and
five-month data for 3,697 patients (99.6%). Key efficacy
outcomes (death, MI, strokes and readmission to the
hospital for UA) and safety outcomes (major bleeding) were
adjudicated by a central committee that had no knowledge
of the treatment allocation. There was a high degree of
agreement in the classification of events between the clinical
sites and central committee (agreement rates of 99.3% for
primary outcomes and 97.7% for secondary outcomes).
Therefore, the steering committee decided to accept the
clinical classification for the few events that could not be
adjudicated (n 5 4).
Statistical analysis. We anticipated an event rate of 9% for
the composite outcome of cardiovascular death/new MI/
stroke and 20% for cardiovascular death/MI/stroke/
readmission to the hospital for UA at five months. With
4,000 patients, we would have 80% power (2a 5 0.05) to
detect a 26% relative risk (RR) reduction in the primary
outcome and a 21% RR reduction in the secondary out-
come.
The rates of the primary and secondary outcomes were
compared by using an intention-to-treat analysis with the
Mantel-Haenszel (log-rank) test, stratified by center (11).
Although an efficacy analysis was prespecified in the proto-
col, its exact nature was only determined after observing the
unexpectedly large variation in compliance to oral ACs
between various countries (49% to 90%) at one month.
Details of the analyses were specified with no knowledge of
event rates or treatment effects; only compliance rates were
known. The countries were ranked solely according to their
rates of compliance to allocated oral ACs at 35 days (a time
when approximately one-half of the events had occurred).
Those countries with $70% of patients receiving study
medication at 35 days (six countries; n 5 1,821) were
considered to be “good” compliers, and those countries with
,70% were considered to be “poor” compliers (eight coun-
tries; n 5 1,891). The 70% cutoff also approximately
corresponded to the average compliance rates in previous
post-MI trials of warfarin with a positive result (11). The
same analyses were conducted by dividing centers into good
compliers ($70% compliance at 35 days; 149 centers, n 5
2,008) and poor compliers (,70% compliance at 35 days;
140 centers, n51704).
An independent Data and Safety Monitoring Board
conducted three interim analyses. For efficacy, the combined
outcomes of cardiovascular death and new MIs were mon-
itored using a boundary corresponding to 4 SDs for the first
half of the study and 3 SDs for the second half. In addition,
the boundaries had to be crossed on two successive analyses
at least three months apart for consideration of early
termination because of efficacy. These extreme boundaries
Abbreviations and Acronyms
AC(s) 5 anticoagulation or anticoagulants
CI 5 confidence interval
INR 5 International Normalized Ratio
MI 5 myocardial infarction
OASIS 5 Organization to Assess Strategies for
Ischemic Syndromes
RR 5 relative risk
UA 5 unstable angina
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require practically no adjustment of the p value, so p , 0.05
was considered to be statistically significant. An analysis
stratified by randomization to hirudin or heparin yielded no
evidence of heterogeneity. Therefore, only the overall results
are presented.
RESULTS
Study group. During the period from August 1996 to
April 1998, 10,141 patients were recruited into the main
study comparing hirudin versus heparin (Fig. 1). The AC
substudy was not implemented until May 1997, by which
time 1,743 patients were already randomized into the main
trial. Of the remaining patients, 4,686 were not included
because of the physician’s reluctance to enroll patients (n 5
1,814 [17.9%]), patient refusal (n 5 1,246 [12.3%]),
planned bypass surgery (n 5 385 [3.8%]), indication for
warfarin (n 5 130 [1.3%]), contraindication to warfarin
(n 5 119 [1.2%]) or no significant coronary artery disease
(n 5 93 [0.9%]).
A total of 3,712 patients were randomized. Their baseline
characteristics and those of the nonrandomized patients are
summarized in Table 1. Apart from a higher rate of use of
prerandomization heparin in excluded patients (which is
explained by the varying rates of inclusion of patients by
countries and the patterns of their heparin use), there were
no clinically important differences in baseline characteristics.
Overall results. COMPLIANCE AND INR. Of the 1,848 pa-
tients assigned to oral AC therapy, the cumulative propor-
tion of patients who had stopped warfarin was 18.3% at
seven days, 28.7% at 35 days, 31.9% at three months and
36.3% at five months. The proportion of patients with INR
$2.0 among those taking oral ACs was 55.3% at seven days,
70.2% at two weeks, 65.3% at 35 days, 71.8% at three
months and 77.3% at five months. The main reasons for
discontinuation of oral ACs included a reported need for
cardiac catheterization, percutaneous transluminal coronary
angioplasty or bypass surgery (n 5 211 [11.4%]), patient
refusal (n 5 103 [5.5%]), bleeding (n 5 84 [4.5%]) or
physician decision (n 5 77 [4.2%]). In the control group,
1.9% were prescribed an oral ACs at seven days, 3.4% at 35
days, 3.5% at three months and 3.3% at five months.
CONCOMITANT DRUGS. There were no differences in the
rates of use of aspirin before randomization into the main
study (64% and 65% in the warfarin and control groups,
respectively). However, by discharge and during follow-up,
more patients in the standard therapy arm were taking
aspirin (97% vs. 92% at discharge and 93% vs. 83% at five
months; p , 0.001 for both times). The use of all other
drugs was similar at discharge between the two groups.
Efficacy and safety outcomes at five months (Table 2). A
total of 140 (7.6%) patients experienced the primary out-
come in the oral AC group compared with 155 subjects
(8.3%) in the control group (RR 0.90, 95% confidence
interval [CI] 0.72 to 1.14; p 5 0.40). Three hundred and
eight (16.7%) patients experienced the secondary outcome
in the oral AC group compared with 327 subjects (17.5%) in
the control group (RR 0.95, 95% CI 0.81 to 1.1; p 5 0.53).
There was an excess of major bleeding (49 vs. 25; RR 2.0;
p 5 0.004) and minor bleeding (85 vs. 50; RR 1.73; p 5
0.002) with oral ACs. The proportion of patients with
life-threatening bleeding accounted for about one-half of all
major bleeding cases (warfarin [n 5 25] 1.4% vs. control
[n 5 14] 0.8%; p 5 0.07). The proportion of patients
undergoing cardiac catheterization was lower in the oral AC
group (679 [36.8%] vs. 752 [40.4%]; p 5 0.03), but there
were no differences in the rates of coronary angioplasty (232
vs. 215) or bypass surgery (225 vs. 257).
Subgroup results by compliance (Table 3). BY COUNTRY
OR CENTER. Of the patients entering the main part (i.e.,
hirudin vs. heparin) of the trial, good-complier countries
(35-day rates of oral AC use $70%) had lower rates of
patient exclusions before the second randomization (AC vs.
control) compared with poor-complier countries for physi-
cian (545 [13.0%] vs. 1,269 [21.3%]) or patient refusal (442
[10.5%] vs. 804 [13.5%]) or exclusions for planned bypass
surgery (82 [2.0%] vs. 303 [5.1%]). These data indicate a
greater willingness to participate in the oral AC part of the
study in the former category of countries. This led to a
higher proportion of patients being randomized in the
good-complier countries (43.4%) compared with the poor-
complier countries (31.8%; p , 0.001). In the good-
complier countries, only 10.4% of patients had discontinued
oral ACs at seven days and 23.6% at five months, compared
with 27.6% and 44.9%, respectively, in the poor-complier
countries (p , 0.001 at both times). The proportion of
patients who achieved an INR .2.0 by hospital discharge
was 64.1% in the good-complier countries compared with
35.2% in the poor-complier countries (p , 0.001).
In the good-complier countries, there was a significant
reduction in the primary outcome of cardiovascular death,
MI or stroke (55 [6.1%] in the oral AC group vs. 81 [8.9%]
in the control group; RR 0.68, 95% CI 0.48 to 0.95; p 5
0.02) compared with no effect in the poor-complier coun-
tries (85 [9.0%] vs. 74 [7.8%], respectively; RR 1.17, 95%
CI 0.86 to 1.6; p 5 0.33) (p 5 0.02 [for heterogeneity])
(Fig. 2). A similar pattern was observed with the secondary
outcome, with an apparent benefit observed in the good-
complier countries (108 [11.9%] vs. 151 [16.5%], respec-
tively; RR 0.70, 95% CI 0.55 to 0.90; p 5 0.005), with
no benefit in the poor-complier countries (200 [21.3%] vs.
176 [18.5%], respectively; RR 1.16, 95% CI 0.95 to 1.41;
p 5 0.16) (p 5 0.002 [for heterogeneity]). An analysis
dividing centers into good and poor compliers provided
consistent results for both the primary and secondary
outcomes (Fig. 3).
The overall rates of procedures in the good compliance
countries versus poor compliance countries were signifi-
cantly lower (28.4% vs. 54.1%; p 5 0.001). In addition,
there were also reductions in the use of cardiac catheteriza-
tion (22.8% vs. 28.7%; p 5 0.004) and coronary revascular-
ization (15.0% vs. 18.3%; p 5 0.059) with oral ACs
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compared with standard (control) therapy in the good-
complier countries. In contrast, there was no difference in
these events between the active and control groups among
the poor-complier countries (50.4% vs. 51.7% for catheter-
ization and 32.9% vs. 30.8% for coronary revascularization)
(p 5 0.06 and 0.04 for interactions, respectively, comparing
the results of the two categories of countries). The reasons
for patients stopping medications in the poor-complier coun-
tries were more likely to be due to an invasive procedure (27.5%
vs. 10.6%; p , 0.001) or physician decision (8.9% vs. 6.0%;
p 5 0.015). However, bleeding as the reason for stopping the
medication was higher, but not significantly so, in the good-
Figure 1. Study group. AC 5 anticoagulants; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease.
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complier group (8.5% vs. 6.6%; p 5 0.125), which is consistent
with more intensive AC in these countries.
COMPLIANCE BY PATIENTS. Figure 1 provides the data on
both the primary and secondary outcomes among patients
who were adherent compared with those who were not in
the active and control groups. The rates of primary and
secondary outcomes were similar (high) in the patients who
were not adherent (primary outcome: 14.9% [77 of 518] vs.
14.0% [12 of 83]; secondary outcome: 27.6% [143 of 518]
vs. 26.5% [22 of 83]). However, among those adherent to
the treatment allocation, both the primary and secondary
outcomes appeared to be reduced substantially (primary
outcome: 4.7% [63 of 1,330] active treatment vs. 8.0% [143
of 1,781] control; secondary outcome: 12.4% [165 of 1,330]
active treatment vs. 17.1% [305 of 1,781] control). Al-
though promising, there are several intrinsic limitations of
this analysis, as discussed later.
Events in the month after cessation of therapy. The
number of additional patients who had the primary outcome
(14 vs. 15) or the secondary outcome (26 vs. 31) in the
month after cessation of oral AC therapy was similar,
Table 1. Warfarin Substudy: Baseline Characteristics at Study Entry
Oral AC Group
(n 5 1,848)
Standard
Therapy Group
(n 5 1,864)
Nonrandomized
Group
(n 5 6,429)*
Mean 6 SD age (years) 64 6 10 64 6 10 64 6 11
Females 710 (38.4%) 764 (41.0%) 2490 (38.7%)
Aspirin use 1184 (64.1%) 1213 (65.1%) 4463 (69.5%)
ECG changes on admission 1683 (91.1%) 1716 (92.1%) 5796 (90.2%)
Prerandomization heparin 408 (22.1%) 407 (21.8%) 2047 (31.8%)
Unstable angina 1594 (86.3%) 1632 (87.6%) 5663 (88.1%)
Non–Q wave MI 254 (13.7%) 230 (12.3%) 765 (11.9%)
Previous MI 714 (38.6%) 704 (37.8%) 2513 (39.1%)
Stable angina 711 (38.5%) 687 (36.9%) 2487 (38.7%)
Other CAD 991 (53.6%) 999 (53.6%) 3658 (56.9%)
History of CABG 226 (12.2%) 211 (11.3%) 839 (13.1%)
History of PTCA 83 (4.5%) 113 (6.1%) 520 (8.1%)
History of catheterization 268 (14.5%) 295 (15.8%) 1219 (19.0%)
History of stroke 68 (3.7%) 72 (3.9%) 281 (4.4%)
History of hypertension 967 (52.3%) 1025 (55.0%) 3469 (54.0%)
History of heart failure 145 (7.8%) 137 (7.4%) 519 (8.1%)
History of diabetes 354 (19.2%) 382 (20.5%) 1396 (21.7%)
Current smoking 412 (22.3%) 397 (21.3%) 1501 (23.4%)
Former smoking 730 (39.5%) 707 (37.9%) 2602 (40.5%)
*1,743 patients were excluded before the availability of study drugs. Data are presented as the number (%) of subjects, except for age.
AC 5 anticoagulation; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; ECG 5 electrocardiographic; MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty.
Table 2. Overall Results at Five Months
Oral AC
(n 5 1,848)
Standard Therapy
(n 5 1,864) RR (95% CI) p Value
Efficacy outcomes
CVD, MI, stroke 140 (7.6%) 155 (8.3%) 0.90 (0.72–1.14) 0.40
CVD, MI, stroke, RFA* 308 (16.7%) 327 (17.5%) 0.95 (0.81–1.11) 0.53
CVD, MI, stroke, RFA* with ECG changes 231 (12.5%) 252 (13.5%) 0.92 (0.77–1.10) 0.34
CVD 74 (4.0%) 69 (3.7%) 1.08 (0.78–1.51) 0.63
New MI 89 (4.8%) 95 (5.1%) 0.94 (0.71–1.26) 0.69
All strokes 11 (0.6%) 18 (1.0%) 0.62 (0.29–1.31) 0.2
Ischemic strokes 5 (0.3%) 14 (0.8%) 0.36 (0.13–1.00) 0.04
Procedures after randomization
Cardiac catheterization 679 (36.8%) 752 (40.4%) 0.91 (0.84–0.99) 0.03
PTCA 232 (12.6%) 215 (11.6%) 1.09 (0.92–1.30) 0.33
CABG 225 (12.2%) 257 (13.8%) 0.88 (0.75–1.04) 0.15
PTCA/CABG 445 (24.1%) 460 (24.7%) 0.98 (0.87–1.09) 0.69
Safety outcomes
Major bleeding† 49 (2.7%) 25 (1.3%) 1.99 (1.23–3.22) 0.004
Life-threatening bleeding† 25 (1.4%) 14 (0.8%) 1.81 (0.94–3.48) 0.07
Minor bleeding 85 (4.6%) 50 (2.7%) 1.73 (1.22–2.45) 0.002
*RFA 5 refractory angina or readmission to the hospital for unstable angina. †Includes hemorrhagic strokes. Data are presented as the number (%) of subjects.
CI 5 confidence interval; CVD 5 cardiovascular deaths; RR 5 relative risk; other abbreviations as in Table 1.
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indicating no obvious “rebound” in clinical events after
cessation of warfarin.
Pooled analysis of trials of warfarin in unstable angina
(Table 4). When combining the data from the four studies
that evaluated moderate-intensity oral ACs in addition to
aspirin (OASIS-1 [9], OASIS-2, Antithrombotic Therapy
in Acute Coronary Syndromes [ATACS] pilot and
ATACS [10]), 7.4% (155 of 2,088) of patients suffered
from death, MI or stroke in the warfarin group, compared
with 8.8% (186 of 2,104) in the control group (RR 0.83,
95% CI 0.66 to 1.03; p 5 0.10). If the pooled analysis
included only the data from good-complier centers from
OASIS-2, the combined results are more promising (RR
0.62, 95% CI 0.45 to 0.84), but these data should be
interpreted with considerable caution.
DISCUSSION
Results vary by compliance. Our data suggest that despite
the use of aspirin, the rates of cardiovascular death, MI and
stroke are substantial in patients with UA during long-term
follow-up. Overall, we observed a modest, nonsignificantly
lower rate of ischemic events with oral ACs compared with
standard (control) therapy. However, the overall results are
likely to be an underestimate due to the high rates of
noncompliance to oral ACs in some countries or centers.
Therefore, a subgroup analysis of countries and centers
based on compliance was performed. In countries or centers
Figure 2. The top panels provides the hazard rates in the good-complier countries for the primary and secondary outcomes. Note the significant reductions
in both outcomes. The bottom panels provides the hazard rates in the poor-complier countries and indicates no benefit. There is significant heterogeneity
in the treatment effects in these two categories of countries (p 5 0.02 for primary outcome and p 5 0.004 for secondary outcome). CV 5 cardiovascular.
MI 5 myocardial infarction; UA 5 unstable angina.
Figure 3. Primary and secondary outcomes at 150 days in good-complier
($70% at 35 days) and poor-complier (,70% at 35 days) centers. Solid
bars 5 oral anticoagulant; open bars 5 standard therapy. *Tests for
interaction.
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with high compliance to oral ACs, improved outcomes,
lower rates of cardiac interventions and higher bleeding
rates were observed among patients randomized to the
active group compared with those in the control group. The
differences in both the primary and secondary outcomes
between oral AC and control therapy were also statistically
heterogeneous when comparing the results among centers
or countries with good versus poor compliance. The sub-
group analysis by compliance was not originally specified in
the protocol, as we did not anticipate the poor compliance
observed in several countries. When we observed highly
variable compliance rates, we ranked countries by compli-
ance without knowledge of the results in individual coun-
tries. We used a “cutoff” of compliance at 35 days above or
below 70% “blindly.” This divided the number of patients
into two approximately equal halves with markedly different
proportions achieving the target INR (64.1% vs. 35.2%).
The 70% cutoff value also roughly corresponds to the
average compliance in the post-MI trials of oral ACs (9),
which indicated clinical benefit. The same cutoff value was
also used in the analysis of results by compliance using each
center as a unit. Although our approach does not have the
force of a prospectively stated subgroup analysis, it is both
biologically and pharmacologically plausible. Moreover,
such an approach is methodologically valid, as it preserves
an intention-to-treat analysis. Because each hospital was a
strata for randomization, the subgroup analysis is a “proper”
one, as it is based on a prerandomization variable, and the
groups compared (active and control groups within each
strata) would be expected to be similar (12). Second, the
analysis was not “data-dredged,” but postulated and con-
ducted without knowledge of the results. Third, the consis-
tency of the results across three sets of efficacy outcomes
(lower rates of primary outcomes of the composite of
cardiovascular death/MI/stroke; lower rates of secondary
outcomes of the composite of cardiovascular death/MI/
stroke/readmission to the hospital for UA; and lower rates
of invasive procedures), coupled with higher rates of major
bleeding, is both biologically and pharmacologically plausi-
ble and consistent with external data. However, subgroup
analyses may lead to an exaggeration of the magnitude of
benefit observed among the good-complier countries/
centers (approximately one-third risk reduction), and the
true benefit in the good-complier countries may be lower.
This possibility is counterbalanced by the fact that a
significant proportion of patients (24%) had stopped taking
oral ACs, even in the good-complier countries; only approx-
imately one-third of patients had achieved an INR .2.0;
and the proportion continuing to use aspirin after random-
ization was lower in the warfarin group. Therefore, the
benefit among those who actually took oral ACs may be
higher than that of the overall treatment and closer to the
actual difference observed in the good-complier countries.
This is consistent with an apparently large benefit (RR 0.59
for primary outcome and RR 0.72 for secondary outcomes)
when patients who adhered to the original allocation were
compared. However, such an analysis is based on a postran-
domization variable, and the two groups (active vs. control)
are not comparable. Nevertheless, these analyses are consis-
tent with the more proper analyses (stratification by coun-
tries or by centers) and provide evidence that if a high level
of adherence can be achieved, oral ACs are likely to be
effective.
These exploratory analyses need confirmation in prospec-
tive trials of oral ACs that ensure high rates of compliance.
When combining the overall data from OASIS-2 with data
from three previous small trials of warfarin in UA/non–Q
wave MI, including the OASIS pilot (9) and ATACS study
(10), a promising risk reduction in death, MI and stroke of
;17% can be seen, further supporting the possibility that
oral ACs are effective when given in addition to aspirin. In
this analysis, the overall OASIS-2 results were used, and the
real benefit in centers that maintain a high degree of
compliance is likely to be greater. In addition to the
aforementioned data, the results of a U.K. trial of high risk
individuals indicate a benefit of warfarin (INR ;1.5) when
added to aspirin (13).
Compliance is related to practice patterns. The data from
the subgroup analyses of the OASIS-2 trial indicate clearly
different patterns of practice (e.g., higher invasive procedure
rates) among various countries, which is also associated with
an initial reluctance to enter patients into the warfarin
substudy, followed by higher rates of noncompliance once
the patients were randomized. Not only do these variations
in clinical practice have implications for the conduct of
clinical trials of antithrombotic agents in different kinds of
Table 4. Meta-Analysis of All Trials Evaluating Moderate-Intensity Oral Anticoagulation in
Addition to Aspirin in Patients With Unstable Angina
Oral
Anticoagulant
Standard
Therapy
RR
(95% CI)
p
Value
OASIS-1 5/98 (5.1%) 13/99 (13.1%) 0.39 (0.14–1.05) 0.051
OASIS-2 142/1,848 (7.7%) 160/1,864 (8.6%) 0.89 (0.71–1.12) 0.32*
ATACS-P 0/37 (0.0%) 1/32 (3.1%) 0.29 (0.01–6.87) 0.28
ATACS 8/105 (7.6%) 12/109 (11.0%) 0.69 (0.30–1.62) 0.395
Total 155/2,088 (7.4%) 186/2,104 (8.8%) 0.83 (0.66–1.03) 0.10*
*If the data from OASIS-2 “good complier” countries are used (see Table 3), the pooled results are 68/1,148 (5.9%) for warfarin
and 108/1,153 (9.4%) for standard therapy (RR 0.62, 95% CI 0.45 to 0.84; p 5 0.002). Data are presented as the number (%)
of subjects.
ATACS(-P) 5 Antithrombotic Therapy in Acute Coronary Syndromes (pilot); OASIS 5 Organization to Assess Strategies
for Ischemic Syndromes; other abbreviations as in Table 2.
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centers or countries, but they also may have a potentially
adverse impact on patient outcomes (14). Liberal or routine
use of invasive coronary procedures has not been consis-
tently shown to be superior to a more selective strategy
where cardiac catheterization is reserved for patients with
provocable or recurrent ischemia (15). Further, some trials
indicate a worse outcome with an aggressive approach (16).
In our trial, we observed no difference in the control group’s
event rates between good-complier countries and poor-
complier countries, despite marked differences in interven-
tion rates. A further potential downside associated with a
practice pattern where invasive procedures are common was
observed in this trial. If clinicians do not use antithrombotic
agents (which are potentially beneficial) because of concerns
of bleeding during cardiac catheterization, they may be
denying patients the benefits of potentially helpful thera-
pies. Therefore, there is an urgent need to conduct random-
ized trials that evaluate the effects of long-term antithrom-
botic therapies as well as determine whether a liberal
invasive strategy is helpful in patients with UA. Our trial
also demonstrates a general point: predefined beliefs and
differences in practice patterns may also influence the
efficacy of treatments. This suggests that long-term anti-
thrombotic therapies may be best evaluated in countries or
centers where there is a more conservative approach to the
use of invasive procedures, unless special attention is paid to
maintaining high compliance to such therapies.
Need for more effective and simple long-term therapy.
The data from our trial confirm the relatively high rates of
recurrent ischemic events after hospital discharge in these
patients, despite the widespread use of aspirin. Conven-
tional antithrombotic strategies have focused largely on the
first week after the onset of symptoms. However, only
approximately one-third of the ischemic events that we
observed at six months were observed in the first week.
Therefore, there is an urgent need to develop effective and
acceptable long-term strategies (e.g., prolonged antithrom-
botic therapies) in patients with UA or non–Q wave MI.
The disappointing results in the long term with the new oral
glycoprotein IIb/IIIa agents (17) and with long-term use of
subcutaneous low molecular weight heparin (18–20), com-
bined with the reluctance of some physicians in our study to
use oral ACs optimally, suggest that other simple and safe
treatments are needed. Several trials of patients undergoing
stent placement after coronary angioplasty indicate that the
combination of aspirin plus thienopyridine (e.g., ticlopidine
or clopidogrel) has a synergistic effect and may be superior
to warfarin in preventing subacute coronary occlusion (21–
24). This combination of antiplatelet agents was also safer
than oral ACs. If the benefits and safety of aspirin plus a
thienopyridine antiplatelet agent can be confirmed during
long-term therapy after UA, this relatively simple regimen is
more likely to be accepted into clinical practice. This
hypothesis is being tested in the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) study (25).
Conclusions. Only a small, nonsignificant overall benefit
was observed in patients allocated to receive warfarin. This
is likely due to the poor compliance in several countries
where high rates of invasive procedures are commonly used.
Our exploratory analyses suggest that a regimen of
moderate-intensity oral ACs in countries or centers that are
likely to be compliant adds to the benefits of aspirin in
patients with UA. The differences in the results between the
two sets of countries or centers are biologically plausible
(good compliance to ACs is associated with greater efficacy,
but higher bleeding risk), statistically valid (prerandomiza-
tion stratification variable was used) and internally consis-
tent across three sets of efficacy outcomes, with significant
tests of heterogeneity. Furthermore, combining the overall
results of the current study with previous trials examining
the effect of moderate-intensity oral ACs in addition to
aspirin compared with aspirin alone is also supportive of an
added benefit. This provides support for the conduct of
further trials with warfarin or new antithrombotic or anti-
platelet agents, or both, in patients with UA or MI or in
other groups of patients at high risk of major vascular
events.
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